RxDoctor Payments DataLook up a doctor →

Conigliaro Jones, MD

Family Medicine · Columbia, SCNPI 1811967458

Payments from drug & device makers

$552,269in general payments, 2019–2025

Across 1,047 payments — averaging $527.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$380K
  • AstraZeneca$73K
  • Sanofi-aventis U.S. LLC$44K
  • Pfizer$22K
  • Boehringer Ingelheim France S.a.s.$19K
  • Sanofi US Services Inc.$3K
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$2502%
  • Food & beverage$13,51498%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim31$379,658
AstraZeneca105$73,090
Sanofi-aventis U.S. LLC37$44,305
Pfizer18$22,391
Boehringer Ingelheim France S.a.s.133$19,234
Sanofi US Services Inc.2$3,400
AbbVie(2 entities)208$2,367
GSK61$804
Novo Nordisk40$646
Lilly USA, LLC38$553
Arbor Pharmaceuticals, Inc.31$455
Abbott23$389
Bayer19$364
Takeda Pharmaceuticals U.S.A., Inc.37$329
Currax Pharmaceuticals LLC21$311
Eisai Inc.29$250
Parapro, LLC1$250
Insulet Corporation15$250
Novartis14$248
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$208
Xeris Pharmaceuticals, Inc.9$186
Corcept Therapeutics6$177
Amarin Pharma, Inc.9$171
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)14$167
Biohaven Pharmaceutical Holding Company Ltd.21$135
Amgen7$122
Dexcom, Inc.5$114
Azurity Pharmaceuticals, Inc.6$96
Supernus Pharmaceuticals, Inc.5$93
Clarus Therapeutics Inc.8$93
Merck6$88
Otsuka America Pharmaceutical, Inc.4$78
Esperion Therapeutics, Inc.5$76
Idorsia Pharmaceuticals US Inc4$74
Johnson & Johnson5$74
Ironwood Pharmaceuticals, Inc4$71
Cipher Pharmaceuticals US LLC1$71
Hikma Pharmaceuticals USA4$63
Tolmar, Inc.4$62
Renalytix AI, Inc.3$58
Paratek Pharmaceuticals, Inc.3$56
Exact Sciences3$55
Cequr Corporation2$52
Axsome Therapeutics, Inc.3$50
Alnylam Pharmaceuticals Inc.2$48
Nestle Healthcare Nutrition Inc.3$47
Biohaven Pharmaceuticals, Inc.3$45
Corium, LLC3$44
E.r. Squibb & Sons, L.L.C.3$44
Ultragenyx Pharmaceutical Inc.2$35
Alfasigma USA, Inc.2$28
Valeritas, Inc.1$25
Vivus LLC1$18
Verity Pharmaceuticals Inc.1$17
Metuchen Pharmaceuticals1$17
Daiichi Sankyo Inc.1$17
Shionogi Inc1$16
Phathom Pharmaceuticals, Inc.1$16
Astellas Pharma US Inc1$16
Antares Pharma, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$552,269 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$52,310
Medicare patients
108
Services billed
685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$56,823
BiktarvyBictegrav/Emtricit/Tenofov Ala13$49,878
FarxigaDapagliflozin Propanediol25$38,995
EliquisApixaban43$36,232
MounjaroTirzepatide21$29,004
XareltoRivaroxaban27$28,753
JardianceEmpagliflozin22$27,145
TrulicityDulaglutide20$20,161
KerendiaFinerenone12$15,913
RybelsusSemaglutide11$13,506
LinzessLinaclotide14$10,562
Soliqua 100-33Insulin Glargine/Lixisenatide15$8,412
EntrestoSacubitril/Valsartan11$7,083
NexlizetBempedoic Acid/Ezetimibe13$5,157
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid16$1,986

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$646$70,32960 claims
Lilly USA, LLCMounjaro, Trulicity$553$49,16441 claims
AstraZenecaFarxiga$73,090$38,99525 claims
PfizerEliquis$22,391$36,23243 claims
Johnson & JohnsonXarelto$74$28,75327 claims
Boehringer IngelheimJardiance$379,658$27,14522 claims
BayerKerendia$364$15,91312 claims
AbbVieLinzess, Synthroid$2,367$11,28831 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$44,305$8,41215 claims
NovartisEntresto$248$7,08311 claims
Esperion Therapeutics, Inc.Nexlizet$76$5,15713 claims
Hikma Pharmaceuticals USAMorphine Sulfate$63$94128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →